From Silent Epidemic to Measurable Value

Ipsos
Insights Hub
From Silent Epidemic to Measurable Value

From Silent Epidemic to Measurable Value

Rethinking Alzheimer’s Through a Health Systems Lens

17.11.25

Our latest article reframes Alzheimer’s disease (AD) as a health system risk multiplier, exploring the knock-on effects of the disease and its management on global health systems. Louise Hogg, our Market Access director, explores:

Cost structures: elevated healthcare costs related to heightened risks of health issues outside of disease management
Diagnostic pathways: inequitable diagnosis, treatment, and support structures
Workforce needs: short supply of neurologists and geriatricians in many regions

Download and read the paper to discover Ipsos’ commentary on the real-world evidence (RWE) and health economics and outcomes research (HEOR) opportunities in the Alzheimer’s disease space.

Contact

Louise Hogg

Market Access, Healthcare

Send an email

More insights about Health

Healthcare Publication
The Power of the Patient's Voice: The Importance of PROs in Real-World Evidence
Exploring the landscape of patient-reported outcomes (PROs).
07.10.25
Oncology Publication
Would You Want to Know? The Paradox of Early Cancer Detection
Read our new viewpoint and delve into the paradox of early cancer detection: how expanding screening methods – particularly multi-cancer early detection tests – while life-saving, pose considerations such as psychological impacts, false positives, and ethical dilemmas.
20.08.25
Healthcare Publication
Ipsos launches GLP-1 PersonaBot, designed to support companies’ understanding of the consumer obesity treatment market
Ipsos’ latest AI-powered innovation offers unparalleled insights into the fast-moving consumer obesity treatment market – while reinforcing Ipsos’ position at the forefront of AI applications in market research.
02.07.25